Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Soligenix, Inc. SNGX
$0.76
-$0.01 (-0.88%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2475857.00000000
-
week52high
15.00
-
week52low
0.73
-
Revenue
948911
-
P/E TTM
0
-
Beta
1.74809600
-
EPS
-4.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 11:30
Описание компании
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley FBR | Buy | 04 дек 2020 г. | |
| Dawson James | Neutral | Buy | 28 июл 2020 г. |
| H.C. Wainwright | Neutral | Buy | 31 янв 2018 г. |
| Maxim Group | Buy | Buy | 14 авг 2017 г. |
| H.C. Wainwright | Buy | Buy | 17 июл 2017 г. |
| B. Riley Securities | Buy | 04 дек 2020 г. | |
| HC Wainwright & Co. | Neutral | Buy | 31 янв 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Straube Richard | A | 80000 | 80000 | 08 дек 2022 г. |
| SCHABER CHRISTOPHER J | A | 140000 | 140000 | 08 дек 2022 г. |
| Guarino Jonathan L. | A | 80000 | 80000 | 08 дек 2022 г. |
| Donini Oreola | A | 80000 | 80000 | 08 дек 2022 г. |
| LAPOINTE ANTHONY GREGG | A | 129747 | 46154 | 17 ноя 2022 г. |
| Parks Diane L. | A | 112504 | 46154 | 17 ноя 2022 г. |
| RUBIN ROBERT J. | A | 126753 | 46154 | 17 ноя 2022 г. |
| ZELDIS JEROME B | A | 145285 | 46154 | 17 ноя 2022 г. |
| SCHABER CHRISTOPHER J | A | 90095 | 20000 | 18 мая 2022 г. |
| Straube Richard | A | 8000 | 8000 | 18 мая 2022 г. |
Новостная лента
Soligenix shares spike after T-cell lymphoma candidate HyBryte aces compatibility study results
Proactive Investors
04 мая 2023 г. в 11:14
Soligenix (NASDAQ:SNGX) shares more than doubled on Thursday after the biopharmaceutical company announced positive results from a compatibility study of its investigational therapeutic HyBryte in cutaneous T-cell lymphoma (CTCL) using the commercially ready Daavlin Series 7 visible light device. The company is developing and moving toward the potential commercialization of HyBryte (synthetic hypericin sodium) for the treatment of CTCL, a class of non-Hodgkin's lymphoma.
Soligenix stock slumps as cancer drug application is knocked back
Proactive Investors
14 февр 2023 г. в 10:44
Soligenix (NASDAQ:SNGX) slumped in Tuesday's early deals after revealing its cancer drug has been knocked back by the US Food and Drug Administration. The company, in a statement, told investors that it has received a Refusal to File (RTF) letter from the FDA for its HyBryte new drug application (NDA).
Soligenix Invited to Present at the Virtual Investor Summit Event
PRNewsWire
19 янв 2023 г. в 07:30
Focusing on 25 micro-cap companies with key catalysts and/or strong performance in the current market PRINCETON, N.J. , Jan. 19, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Virtual Investor Summit on January 26, 2023.
7 Stocks to Add to Your 10x Watchlist
InvestorPlace
16 дек 2022 г. в 12:09
There are few things that get growth investors excited like the opportunity to invest in 10x stocks. By definition, these 10x stocks (also referred to as 10 baggers) can add huge gains to your portfolio.
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference
Newsfile Corp
11 ноя 2022 г. в 09:30
Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summit live in NYC at the Sheraton Times Square. Jonathan Guarino, the Company's Senior Vice President and Chief Financial Officer, will be presenting a Company update and attend 1x1 meetings. During the presentation Mr.